# 3SBio Inc.

3SBio Inc. is an other based in Shenyang, China.

## Overview

- **Organization type:** other
- **Headquarters:** Shenyang, China
- **Region:** North America
- **Address:** Shenyang, Liaoning, China
- **Founded:** 1993
- **Assets under management:** Undisclosed
- **Website:** www.3sbio.com
- **LinkedIn:** https://www.linkedin.com/company/3sbio-inc.

## Regulatory record

- **Reports private funds:** No

## About

3SBio Inc., established in 1993 by Chairman and CEO Jing Lou, is a Chinese biotechnology company focused on the research, development, manufacture, and commercialization of recombinant protein drugs and biosimilars. The firm began as a small R&D venture in Shenyang and listed on the Hong Kong Stock Exchange in 2015, raising roughly $700 million in its IPO (per Reuters, 2015). 3SBio's strategy centers on in-house development of complex biologics and strategic licensing from Western partners. Its marketed portfolio includes EPO products (epoetin alfa), thrombopoietin agonists (rhTPO), and biosimilars for autoimmune diseases. The company has a pipeline across oncology, nephrology, and ophthalmology, with a strong focus on the Chinese market. Over the years it has in-licensed assets from companies like Takeda, Swedish Orphan Biovitrum, and Bellicum Pharmaceuticals. The firm operates manufacturing facilities in Shenyang and Shanghai, and maintains commercial and regulatory offices in Beijing and Menlo Park, California. It employs a sales force of roughly 2,000 covering hospitals across China. In 2023 the firm began commercializing a biosimilar of aflibercept for ophthalmology, licensed from a European biotech (per 3SBio press release, March 2023). 3SBio's structural differentiator is its dual identity: it is both a fully integrated Chinese biopharma with a revenue-generating product portfolio and a public company governed by Hong Kong listing rules, giving it transparency and corporate governance standards atypical for Chinese biotechs. This hybrid — public, profitable, and still founder-controlled — makes it a unique entity in Chinese biotech.

## Sectors

- Biotech
- Pharmaceuticals
- Healthcare Services

## Offices

- Menlo Park, CA, United States
- Shanghai, China
- Beijing, China

## People

- Jing Lou — Chairman of the Board & Chief Executive Officer
- David Pinchot — Chief Financial Officer
- Hui Chen — Senior Vice President, R&D

## Questions

### Who founded 3SBio Inc. and when was the firm established?

Jing Lou founded 3SBio in 1993. He remains Chairman and CEO. The company listed on the Hong Kong Stock Exchange in 2015.

### What therapeutic areas does 3SBio focus on?

Its marketed products and pipeline concentrate on nephrology (e.g., EPO), oncology (e.g., rhTPO), immunology (biosimilars), and ophthalmology (aflibercept biosimilar).

### How does 3SBio source its drug pipeline?

The firm combines internal R&D with in-licensing of late-stage biologics from Western biotechs. It has partnered with Takeda, Swedish Orphan Biovitrum, and Bellicum Pharmaceuticals to bring assets into China.

### Where are 3SBio's facilities located?

The firm's headquarters and principal manufacturing are in Shenyang, with additional manufacturing and R&D in Shanghai, and commercial/regulatory offices in Beijing and Menlo Park, California.

### Has 3SBio raised public capital, and is it profitable?

3SBio raised approximately $700 million in its 2015 Hong Kong IPO. The firm has been operationally profitable in most recent fiscal years, with its marketed product portfolio generating recurring revenue.

## Related profiles

- [Avon Machining](https://altss.com/profile/avon-machining)
- [Indocan Honey Pvt Ltd.](https://altss.com/profile/indocan-honey-pvt-ltd)

---

Last updated: 2026-06-03T20:00:00.000Z

Canonical page: https://altss.com/profile/3sbio-inc

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology